

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

| Adverse Events | Placebo (N=86) | Xanomeline High Dose (N=84) | Xanomeline Low Dose (N=84) |
|--|-------------------|-----------------------------------|----------------------------------|
| ABDOMINAL DISCOMFORT | 0 | 1 | 0 |
| ABDOMINAL PAIN | 1 | 2 | 3 |
| ACROCHORDON EXCISION | 0 | 1 | 0 |
| ACTINIC KERATOSIS | 0 | 1 | 0 |
| AGITATION | 2 | 1 | 2 |
| ALCOHOL USE | 0 | 1 | 0 |
| ALLERGIC GRANULOMATOUS ANGIITIS | 0 | 1 | 0 |
| ALOPECIA | 1 | 0 | 0 |
| AMNESIA | 0 | 2 | 0 |
| ANXIETY | 2 | 0 | 4 |
| APPLICATION SITE BLEEDING | 0 | 0 | 1 |
| APPLICATION SITE DERMATITIS | 9 | 12 | 15 |
| MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term. | | | |

Dataset: ADAE | Cutoff: 01JAN2023

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

| Adverse Events | Placebo (N=86) | Xanomeline High Dose (N=84) | Xanomeline Low Dose (N=84) |
|--|-------------------|-----------------------------------|----------------------------------|
| APPLICATION SITE DESQUAMATION | 0 | 0 | 1 |
| APPLICATION SITE DISCHARGE | 0 | 1 | 0 |
| APPLICATION SITE DISCOLOURATION | 0 | 0 | 1 |
| APPLICATION SITE ERYTHEMA | 3 | 23 | 20 |
| APPLICATION SITE INDURATION | 1 | 0 | 0 |
| APPLICATION SITE IRRITATION | 7 | 16 | 18 |
| APPLICATION SITE PAIN | 0 | 2 | 0 |
| APPLICATION SITE PERSPIRATION | 0 | 3 | 0 |
| APPLICATION SITE PRURITUS | 10 | 35 | 33 |
| APPLICATION SITE REACTION | 2 | 1 | 0 |
| APPLICATION SITE SWELLING | 0 | 3 | 1 |
| APPLICATION SITE URTICARIA | 0 | 1 | 2 |
| MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term. | | | |

Dataset: ADAE | Cutoff: 01JAN2023

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

| Adverse Events | Placebo (N=86) | Xanomeline High Dose (N=84) | Xanomeline Low Dose (N=84) |
|--|-------------------|-----------------------------------|----------------------------------|
| APPLICATION SITE VESICLES | 2 | 6 | 5 |
| APPLICATION SITE WARMTH | 0 | 0 | 2 |
| ARTHRALGIA | 1 | 1 | 4 |
| ARTHRITIS | 2 | 1 | 0 |
| ASTHENIA | 2 | 1 | 0 |
| ATRIAL FIBRILLATION | 1 | 5 | 1 |
| ATRIAL FLUTTER | 0 | 2 | 1 |
| ATRIAL HYPERTROPHY | 2 | 0 | 0 |
| ATRIOVENTRICULAR BLOCK FIRST DEGREE | 1 | 0 | 1 |
| ATRIOVENTRICULAR BLOCK SECOND DEGREE | 2 | 4 | 0 |
| BACK PAIN | 2 | 4 | 1 |
| BALANCE DISORDER | 0 | 0 | 3 |
| MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term. | | | |

Dataset: ADAE | Cutoff: 01JAN2023

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

| Adverse Events | Placebo (N=86) | Xanomeline High Dose (N=84) | Xanomeline Low Dose (N=84) |
|--|-------------------|-----------------------------------|----------------------------------|
| BENIGN PROSTATIC HYPERPLASIA | 2 | 1 | 0 |
| BIOPSY | 0 | 1 | 0 |
| BIOPSY PROSTATE | 0 | 1 | 0 |
| BLISTER | 0 | 2 | 8 |
| BLOOD ALKALINE PHOSPHATASE INCREASED | 1 | 0 | 0 |
| BLOOD CHOLESTEROL INCREASED | 0 | 1 | 0 |
| BLOOD CREATINE PHOSPHOKINASE INCREASED | 2 | 0 | 0 |
| BLOOD GLUCOSE INCREASED | 0 | 2 | 1 |
| BLOOD URINE PRESENT | 1 | 0 | 0 |
| BODY TEMPERATURE INCREASED | 0 | 0 | 1 |
| BRADYCARDIA | 4 | 0 | 0 |
| BRONCHITIS | 1 | 0 | 0 |
| MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term. | | | |

Dataset: ADAE | Cutoff: 01JAN2023

Complete Adverse Events Summary
All Treatment Groups - Multi-page Table

| Adverse Events | Placebo (N=86) | Xanomeline High Dose (N=84) | Xanomeline Low Dose (N=84) |
|--|-------------------|-----------------------------------|----------------------------------|
| BUNDLE BRANCH BLOCK LEFT | 1 | 0 | 0 |
| BUNDLE BRANCH BLOCK RIGHT | 2 | 0 | 1 |
| MedDRA version 25.0 coding applied. Table includes all reported adverse events regardless of relationship to study drug. Events sorted alphabetically by preferred term. | | | |

Dataset: ADAE | Cutoff: 01JAN2023